NeuroTherapy Research Hub

Alzheimer's Neuromodulation Data

• 🔥 Cognito Therapeutics Spectris: In the OVERTURE feasibility study, 24-week Spectris gamma stimulation...

Key Alzheimer’s breakthrough: A-beta competes with tau for microtubule binding sites inside neurons, displacing tau and disrupting transport.

-...

Personalized stem cell therapy sasineprocel improved symptoms and quality of life in 8 early PD patients:

• Low-dose group: 51.6% symptom improvement...

Promising OVERTURE results: 24-week Spectris gamma light/sound stimulation attenuated EEG power shifts from high to low frequencies, restoring...

Acumen Pharmaceuticals presented key studies at the Advances in Alzheimer's Treatment conference:

• Enhanced Brain Delivery™ innovations
• Biomarker research
• Novel antibodies
  These advances target amyloid clearance and BBB breakthroughs for Alzheimer's.

Bezisterm, BioVie's inflammation modulator, shows promising safety and efficacy in early clinical results:

• Slowed cognitive decline in Alzheimer’s patients
• Improved motor control in Parkinson’s
  Phase 2/3 trials ongoing with key readouts soon.

Key advantages of ARA-290, an EPO-derived peptide:

• No erythropoiesis risk: Selectively binds IRR for tissue repair and anti-inflammation.
  -...

Ongoing trials target toxic beta-amyloid aggregates in prodromal Alzheimer's, removing them to potentially slow progression. Track Clinicaltrials.eu for updates on these RCTs.

Zervimesine shows potential to slow DLB progression and reduce associated neuropsychiatric symptoms, based on Cognition Therapeutics' clinical data.

LINC00641 emerges as a promising diagnostic biomarker and therapeutic candidate for Alzheimer's disease. Crucially, it requires further validation in animal models to confirm its value.

Phase II Trial Safety Data

• 🔥 Priavoid PRI-002: Priavoid's Phase II study enrolled 304 patients aged 55-80 with mild cognitive impairment or...

Leqembi succeeds not just as a drug, but through the infrastructure it helped build for amyloid therapies.

• Biological confirmation required:...

• Favorable safety profile shown in initial Phase 2 data for PRI-002 in Alzheimer's
• Oral drug avoids ARIA entirely in ongoing Phase II study
• Trial...

• 92.87% accuracy detecting mild cognitive impairment or Alzheimer’s via MRI brain scans from 815 participants aged 69-84
• Early biomarker: Volume...

Key trend: Validated tau biomarkers gain traction with new funding for scalable blood tests.

• ALZpath pTau217 reinforced via broad AD/PD 2026...

Key OVERTURE study findings at AD/PD 2026:

• Reduced EEG slowing in active group vs. sham, shifting to higher frequencies.
• EEG improvements linked...

Diagnostic Approvals

• 🔥 Roche CE Mark for ApoE4 Test: Roche received CE Mark approval for the Elecsys ApoE4 biomarker test, a blood-based...

Emerging platforms are revolutionizing anti-amyloid therapies with better brain delivery and degradation:

• SPYTACs peptides leverage LRP1 to shuttle...

Herantis Pharma, a clinical-stage biotech developing disease-modifying therapies for Parkinson’s, will present HER-096 Phase 1b data at an upcoming event. A pivotal step in validating new Parkinson’s treatments.

Parkinson's research reaches a pivotal stage driven by new iPSC models, yet funding challenges and outdated trials continue to slow drug development.